The annual Point-in-Time (PIT) Count looked different this year as icy streets and freezing temperatures led the city to cancel part of the usual census of people experiencing homelessness in the ...

The point-in-time count this week of Orange County’s population that lives without stable shelter is an important tool. Becks Heyhoe-Khalil, executive director of the nonprofit United to End ...

The number of U.S. convenience stores slightly decreased for the second year in a row, the National Association of Convenience stores said Monday. There are 151,975 c-stores in operation as of Dec. 31 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

DROVE EMOTIONALLY CHARGED ARGUMENTS TO GET PEOPLE TO VOTE AGAINST THEIR IN SANTA CRUZ COUNTY TWO COMPETEING AFFORABLE HOUSING MEASURES WERE ON BOTH MEASURE B AND C ARE TAX INITIATIVES AIMING TO FUND ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with ...

About 70 homeless encampments in the nation’s capital have been taken down in recent months, but those efforts intensified this week after President Donald Trump deployed members of the National Guard ...

MOUNT PLEASANT, S.C. (WCBD) – WCBD News 2 has launched a Connected TV streaming app, WCBD+, offering live news, weather, and original programming – without a paid subscription. For more than 70 years, ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...